Literature DB >> 10373396

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

T J Torphy1, M S Barnette, D C Underwood, D E Griswold, S B Christensen, R D Murdoch, R B Nieman, C H Compton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10373396     DOI： 10.1006/pupt.1999.0181

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN： 1094-5539            Impact factor:   3.410


× No keyword cloud information.
  27 in total

1.  A multiplicity of muscarinic mechanisms: enough signaling pathways to take your breath away.

Authors:  N M Nathanson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Newer drugs for asthma.

Authors:  Meenu Singh
Journal:  Indian J Pediatr       Date:  2004-08       Impact factor: 1.967

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma.

Authors:  Hyung-Geun Moon; You-Sun Kim; Jun-Pyo Choi; Dong-Sic Choi; Chang Min Yoon; Seong Gyu Jeon; Yong Song Gho; Yoon-Keun Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

Review 5.  Clinical pharmacology of Cilomilast.

Authors:  Geoff Down; Sarah Siederer; Sam Lim; Peter Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Authors:  M Profita; G Chiappara; F Mirabella; R Di Giorgi; L Chimenti; G Costanzo; L Riccobono; V Bellia; J Bousquet; A M Vignola
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 7.  Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.

Authors:  Graeme P Currie; Claire A Butler; Wendy J Anderson; Chris Skinner
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

Review 8.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

9.  Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.

Authors:  Donna Donigi Gale; Linda J Landells; Domenico Spina; Alan J Miller; Kate Smith; Terry Nichols; Yakov Rotshteyn; Alfred Tonelli; Peter Lacouture; Ronald M Burch; Clive P Page; Brian J O'Connor
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.